Carotid Artery Disease Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Carotid endarterectomy (CEA) is the surgical removal of atherosclerotic plaque from the carotid artery bifurcation, performed to prevent ischemic stroke caused by thromboembolism from the internal carotid artery—the most common site of extracranial atherosclerosis responsible for stroke. The procedure is performed under general or regional cervical block anesthesia through a longitudinal neck incision over the carotid bifurcation. The internal carotid artery is opened, the plaque removed through the endarterectomy plane, and the arteriotomy closed either primarily or, preferably, with a patch angioplasty using prosthetic or vein material, which reduces restenosis and stroke risk. A temporary intraluminal carotid shunt maintains cerebral blood flow during cross-clamping when monitoring indicates inadequate collateral perfusion. CEA is the gold-standard treatment for symptomatic carotid stenosis of 50% or greater and selected asymptomatic stenosis of 60–70% or more. Carotid artery stenting (CAS) using embolic protection devices is an alternative for high-surgical-risk patients or those with hostile necks. Optimal timing is within 2 weeks of a transient ischemic attack or non-disabling stroke for maximum benefit, as stroke risk is highest in the early post-event period when plaque is most unstable.

The primary indication for CEA is symptomatic carotid stenosis of 50–99%, defined as ipsilateral TIA or non-disabling ischemic stroke within the preceding 6 months. The NASCET and ECST landmark trials definitively demonstrated benefit: for 70–99% symptomatic stenosis, CEA reduces 5-year ipsilateral stroke risk from 26% to 9% (absolute risk reduction 17%). For 50–69% symptomatic stenosis, benefit is moderate (ARR 4.6% at 5 years) and depends on center experience and surgeon stroke/death rate. Asymptomatic carotid stenosis of 60–99% is a weaker indication: the ACAS trial showed a 5-year absolute risk reduction of only 5.9%, and the NNT is 20–30 over 5 years, meaning best medical therapy (antiplatelet plus statin plus risk factor control) may be comparable in modern practice—the CREST-2 trial is examining this question. Other indications include carotid occlusion with contralateral high-grade stenosis, radiation-induced carotid stenosis, carotid web, recurrent stenosis after prior CEA, and bilateral significant carotid stenosis requiring staged repair.

Symptomatic stenosis of 50% or greater is a strong CEA indication when the surgeon's 30-day stroke/death rate is below 6% for symptomatic and below 3% for asymptomatic cases (per SVS and ESC guidelines). Asymptomatic stenosis eligibility requires careful risk-benefit assessment; men under 75 with low surgical risk and life expectancy over 5 years derive most benefit. CEA is preferred over CAS in patients over 70, those with symptomatic stenosis, and those with standard neck anatomy without prior surgery or radiation. CAS is preferred when the neck is hostile (prior surgery, irradiation, high carotid bifurcation, contralateral recurrent laryngeal nerve palsy), or when cardiac or pulmonary comorbidity makes general anesthesia high-risk. Preoperative workup includes carotid duplex ultrasound, CT angiography or MRA of the aortic arch and carotid vessels, cardiac evaluation, creatinine measurement, and continuation of antiplatelet therapy (aspirin through the perioperative period). Neurologic deficit must be stable before proceeding to elective repair. Antiplatelet therapy is not stopped preoperatively.

Treatment depends on symptom status, degree of stenosis, and patient fitness. Carotid endarterectomy (CEA) is the surgical gold standard: a longitudinal arteriotomy over the common carotid and internal carotid artery exposes the atherosclerotic plaque, which is dissected under direct vision in the subadventitial plane and removed en bloc. Primary closure or patch angioplasty (Dacron, bovine pericardium, or autologous vein) is performed to prevent recurrent stenosis. Intraoperative neurological monitoring — electroencephalogram (EEG), somatosensory evoked potentials, or awake neurological testing under local anaesthesia — guides shunt insertion (temporary internal shunt to maintain cerebral perfusion during carotid clamping) decision. CEA is performed under general or regional (cervical plexus block) anaesthesia as a 2–3 hour procedure. Carotid artery stenting (CAS) is performed by interventional radiologists or cardiologists via femoral or brachial access. A distal embolic protection device (EPD) — typically a filter or reversal flow system — is deployed beyond the carotid plaque before stent delivery. A self-expanding carotid stent is deployed across the stenotic segment, followed by balloon angioplasty post-dilation. CAS is preferred over CEA in patients with severe cardiac or pulmonary comorbidity precluding general anaesthesia, contralateral carotid occlusion, radiation-induced stenosis, or prior ipsilateral CEA with restenosis. Best medical therapy (BMT) alone — dual antiplatelet therapy (aspirin plus clopidogrel for 30–90 days followed by single antiplatelet), high-intensity statin, ACE inhibitor/ARB, blood pressure control, and lifestyle modification — achieves excellent outcomes for asymptomatic stenosis under 70% and is combined with all revascularisation approaches.

CEA provides the most durable and evidence-based stroke prevention for significant carotid stenosis. The NASCET trial demonstrated that CEA reduced 2-year ipsilateral stroke risk from 26% to 9% for 70–99% symptomatic stenosis, an absolute risk reduction of 17% with NNT of 6. For 50–69% symptomatic stenosis, 5-year ARR was 4.6%. The ACAS trial for asymptomatic stenosis of 60% or greater showed 5-year aggregate stroke or death reduction from 11% to 5.1% with CEA. Patch angioplasty closure reduces restenosis from 8–10% to 2–3% compared to primary closure. CEA performed within 2 weeks of TIA or minor stroke reduces recurrent stroke by 75–80% compared to delayed surgery at 3–4 months. At experienced centers with rigorous quality monitoring, combined 30-day stroke and death rates are below 3% for symptomatic and below 1.5% for asymptomatic patients. Regional cervical block anesthesia enables awake neurologic monitoring during carotid clamping, potentially reducing shunt-related complications and improving outcomes compared to general anesthesia in some studies.

Stroke is the most serious CEA complication: 30-day ipsilateral stroke risk is below 3% at experienced centers for symptomatic patients, and 1–3% for asymptomatic cases. Perioperative stroke risk is highest during the first 24 hours and usually results from plaque embolization during dissection, carotid cross-clamp ischemia, or hyperperfusion hemorrhage. Cranial nerve injuries are the most common complications: hypoglossal nerve (tongue deviation, 1–3%), marginal mandibular branch of the facial nerve (lower lip weakness, 1–2%), vagus nerve (voice hoarseness), and glossopharyngeal nerve injury. The majority of cranial nerve injuries are neuropraxia and resolve within 6–12 months. Wound hematoma occurs in 3–5% and, if large, can compress the airway requiring urgent evacuation. Hyperperfusion syndrome (severe headache, seizure, intracerebral hemorrhage) affects 1–3% of patients after revascularization of high-grade stenosis, typically within 3–7 days, and requires aggressive blood pressure control. Myocardial infarction occurs in 1–2%. Restenosis develops in 1–5% at 5 years with patch closure. Wound infection is rare at 0.5%. Overall 30-day mortality at experienced vascular surgery centers is below 0.5% for elective CEA.

After CEA, duplex ultrasound of the ipsilateral carotid is performed at 6–8 weeks to confirm patency and absence of significant restenosis or pseudoaneurysm. Contralateral carotid stenosis severity guides surveillance frequency. Annual carotid duplex surveillance thereafter is standard — significant restenosis (greater than 50%) detected on duplex triggers CT angiography to confirm severity and determine whether repeat intervention is needed. After CAS, duplex ultrasound at 1 month, 6 months, then annually monitors in-stent restenosis, which occurs in 5–10% of cases and may require re-dilation. All patients continue single antiplatelet therapy (aspirin 75–100 mg daily) indefinitely. Blood pressure target below 130/80 mmHg is maintained with ACE inhibitor or calcium channel blocker. LDL cholesterol target below 1.8 mmol/L (70 mg/dL) or below 1.4 mmol/L in very high-risk patients requires high-intensity statin (atorvastatin 40–80 mg, rosuvastatin 20–40 mg), with PCSK9 inhibitor (evolocumab, alirocumab) added if target is unmet. Stroke risk remains the primary clinical concern: neurological follow-up for patients with prior TIA or minor stroke is coordinated through a stroke prevention clinic.

Carotid endarterectomy and carotid artery stenting costs vary substantially across healthcare systems. In India, CEA ranges from USD 4,000–10,000 at JCI-accredited centers including Apollo Hospitals, Fortis, and Narayana Health, representing savings of 60–75% versus US pricing. Thailand offers CEA at USD 7,000–15,000 at Bumrungrad International and Bangkok Hospital with internationally trained vascular surgeons. Turkey provides competitive costs at USD 5,000–12,000 in Istanbul and Ankara centers. Mexico offers CEA at USD 6,000–13,000 near the US border, accessible to US patients. In the United States, CEA costs USD 15,000–40,000 including surgeon fee, anesthesia, hospital room, and post-operative monitoring. The United Kingdom performs CEA on the NHS at no direct cost to eligible patients, although waiting times apply for asymptomatic cases. Germany charges EUR 12,000–28,000. Singapore prices CEA at USD 12,000–25,000 at Mount Elizabeth or Gleneagles hospitals. Carotid artery stenting (CAS) is generally 20–30% more expensive than CEA due to stent device costs. Patients traveling abroad should budget for duplex ultrasound surveillance at 1 month and 1 year post-procedure.

Best medical therapy (BMT) alone is appropriate for asymptomatic carotid stenosis under 70%, where the annual stroke risk is approximately 1% — lower than the procedural stroke risk of CEA or CAS in many patients. The CREST-2 trial is evaluating whether BMT has closed the gap with CEA for asymptomatic disease. The ACST-2 trial comparing CEA versus CAS for asymptomatic severe stenosis found equivalent 5-year non-procedural stroke rates, validating both approaches. For symptomatic stenosis 50–99%, urgent intervention — ideally within 2 weeks of TIA or minor stroke — dramatically reduces recurrent stroke risk. Remote endarterectomy using a special dissector that strips plaque through a short arteriotomy without extensive neck dissection is an option for long-segment stenosis. Hybrid procedures combining CAS with simultaneous coronary artery bypass grafting (CABG) are performed at selected centres for patients with concurrent severe coronary and carotid artery disease. Restenosis after CEA may be treated with CAS as the preferred revascularisation technique. Radiation-induced carotid stenosis following head and neck cancer radiotherapy is particularly well-suited to CAS, avoiding re-operation in a scarred radiation field. Emerging flow diversion devices and covered carotid stents are under investigation for complex carotid artery pathology.